Identification of Inhibitors of the Leishmania cdc2‐Related Protein Kinase CRK3
ChemMedChem2011Vol. 6(12), pp. 2214–2224
Citations Over TimeTop 10% of 2011 papers
Laura A. T. Cleghorn, Andrew Woodland, Iain T. Collie, Leah S. Torrie, Neil R. Norcross, Torsten Luksch, Chido Mpamhanga, Roderick G. Walker, Jeremy C. Mottram, Ruth Brenk, Julie A. Frearson, Ian H. Gilbert, Paul G. Wyatt
Abstract
New drugs are urgently needed for the treatment of tropical parasitic diseases such as leishmaniasis and human African trypanosomiasis (HAT). This work involved a high-throughput screen of a focussed kinase set of ~3400 compounds to identify potent and parasite-selective inhibitors of an enzymatic Leishmania CRK3-cyclin 6 complex. The aim of this study is to provide chemical validation that Leishmania CRK3-CYC6 is a drug target. Eight hit series were identified, of which four were followed up. The optimisation of these series using classical SAR studies afforded low-nanomolar CRK3 inhibitors with significant selectivity over the closely related human cyclin dependent kinase CDK2.
Related Papers
- → Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation(2011)84 cited
- → Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts.(1993)324 cited
- → Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1(2016)23 cited
- → Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division(2022)10 cited
- EVALUATION OF DIFFERENT APPROACHES IN LEISHMANIA DIAGNOSIS(2014)